- We are the Pharma Journal directory
The first regulatory approvals for a CRISPR-based medicine in the UK and EU marked a turning point for genomic medicine and set expectations for oncology....
In 2026, the pharmaceutical sector is moving back into a risk on posture, with AI drug discovery shifting from promise to operational impact and a...
The United Kingdom enters 2026 as one of the most active environments in the world for high-paying clinical trials, particularly early phase studies involving healthy...
Cathepsin B (CTSB) is a lysosomal cysteine protease that plays a key role in protein turnover, antigen processing, and immune regulation. It is widely expressed...
For over a century, the discovery of insulin transformed Type 1 Diabetes (T1D) from a fatal diagnosis into a survivable condition. Yet, despite remarkable technological...
The human immune system is a complex network of cells, tissues, and signaling molecules that serves as a defense system. It continuously identifies and eliminates...
Chronic illness drives demand across the NHS and shapes budgets, workforce planning and service design. People living with multiple long-term conditions account for around half...
Antimicrobial resistance is accelerating across health systems and undermining routine care. Surgical prophylaxis, oncology regimens and neonatal medicine all depend on reliable antibiotics, yet resistant...
For patients living with blood cancer or a severe blood disorder, a stem cell transplant is often the turning point between decline and recovery. Yet...
Community pharmacy in the UK has entered a decisive phase. Policy, funding, and data infrastructure now point to a model where pharmacies act as clinical...
Human gene editing sits at a pivotal point in modern medicine. Its capacity to change DNA with precision has moved from conjecture to clinical practice,...
Artificial intelligence is moving from pilot projects to practical tools across the NHS. The policy direction is clear, with a shift to community-based care and...